Oxytocin dose comparison initiated for labor induction in obese gravida women (BMI ≥30)

Induction of labor is a common obstetric procedure, but optimizing protocols for specific patient populations remains crucial. Obesity, defined as a BMI 30 and above, presents unique challenges in labor management, often associated with longer labor durations and increased rates of cesarean sections. Oxytocin, administered as its synthetic analog Pitocin, is the standard agent for labor induction, acting on oxytocin receptors to stimulate uterine contractions. However, the optimal dosing regimen for obese women is not well-established, potentially requiring higher doses due to altered pharmacokinetics or receptor sensitivity, leading to a gap in evidence-based protocols for this growing patient demographic.

This completed Phase 4 randomized controlled trial (NCT03140488), known as the OPS (Obese Pitocin Study) Trial, enrolled a total of 140 gravida women with BMI 30 and above who were undergoing induction of labor. Participants were randomized into two groups to compare different oxytocin dosing regimens. The study group received a high dose of oxytocin (20 units in 1000 ml), while the control group received a low dose of oxytocin (10 units of oxytocin in 1000 ml). The primary objective was to compare the efficacy and safety of these two dosing strategies for inducing delivery in this specific patient population, aiming to identify an optimized protocol.

The provided abstract describes the design and objectives of this clinical trial but does not present any results or findings. Therefore, no specific data, percentages, p-values, or fold-changes can be reported from this abstract. The study has been completed, and its findings are anticipated.